Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Sanofi Overhauls Late-Stage Pipeline

by Lisa M. Jarvis
May 4, 2009 | A version of this story appeared in Volume 87, Issue 18

Sanofi-Aventis is overhauling its pipeline to channel its resources toward what it considers to be more promising projects. The French pharma firm is discontinuing research on 14 drug and vaccine candidates, including seven in Phase II or III trials, after a portfolio review deemed them less innovative, competitive, or effective than existing drugs. Among the Phase III projects being cut are saredutant, a neurokinin-2 receptor antagonist being developed as an antidepressant; AVE5530, a cholesterol-absorption inhibitor that works like Merck & Co.'s Zetia; and a pentavalent vaccine for diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b. With the cuts, Sanofi now has 51 candidates in clinical trials, although it may shed up to four more products in the coming months.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.